anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic pain is recognized as a world-wide problem. Gureje et al (1) demonstrated that 21% of patients presenting for primary care reported persistent pain and were four times more likely to have a depressive disorder than those without pain. One third of patients with persistent pain had a moderate to severe work role impairment (1). Canadian studies have demonstrated that up to 30% of the population suffers from chronic pain (2, 3). By extrapolation it may be expected that between 20-30% of persons living in Nova Scotia suffer from chronic pain.

Chronic pain is associated with significant morbidity and mortality. It is also associated with increased rates of depression, poorer self related health and increased risk of suicidality (2-4). Poor self-rated health has been demonstrated to be a predictor of increased morbidity and mortality (5-7). Tang and Crane (4) demonstrated that persons with chronic pain have a risk of death by suicide twice that of controls and that the lifetime prevalence of suicide attempts was 5-14%. Chronic pain impairs sleep (8) and may be related to abnormal immune function (9-11). As well, there is morbidity and mortality associated with medications used in the treatment of chronic pain. Although opiate medications form a significant part of the pain management armamentarium they are also associated with serious morbidity including sedation, respiratory depression, death and addiction. Death rates from these medications have risen dramatically (12) in recent years. Ives et al (13) report a 32% incidence of opiate misuse in an academic pain management unit. Cicero et al (14) reported that prescription opiate misuse is more common in rural, suburban and small urban areas, similar to the geographic background of Nova Scotia, and concluded that regionally specific risk minimization strategies should be developed.

The proposed Nova Scotia Chronic Pain Collaborative Care Network (NSCPCCN) is a professional development partnership between family physicians and chronic pain and addiction specialists designed to build capacity in the health care system and provide improved pain management to patients. The NSCPCCN will provide community physicians with access to chronic pain and addiction specialists to assist in the management of patients with chronic pain. The current project is designed as a pilot project to determine the feasibility of this program on a large scale. In order to determine the effect of implementation of a mentor- mentee network in the primary care setting, a pilot project will be undertaken to determine the feasibility and logistics of the NSCPCCN.
Part 2B: Cohort A2 will include participants with MMR-proficient/MSS endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage \>=IIIB) disease.
Lifestyle changes, such as moderate physical activity (e.g. brisk walking) have been shown to delay or prevent the development of Type 2 diabetes in patients with obesity and pre-diabetes. Given the clear benefit of exercise in disease prevention and management, evidence-based cost-effective brief interventions are needed to improve patient outcomes related to Type 2 diabetes and associated health disparities.

In America over the last two decades, adult obesity rates have doubled from 15% to 30%. In 1990, no state had an obesity rate over 14%. In 2003, thirty-five states posted obesity rates of over 20%. Tennessee currently ranks fifth in the U.S. for highest rate of adult obesity. In 2003, direct medical costs associated with obesity totaled an estimated $1.84 billion in Tennessee. Medicare ($433 million) and Medicaid ($488 million) absorbed approximately 50% of these medical costs. Obesity is closely linked with such diseases as heart disease, stroke, diabetes, and certain cancers. In both East and South Nashville, cancer, heart disease, and stroke are listed as three of the top five causes of death with significant racial, educational, and economic disparities.

Reducing socioeconomic and racial/ethnic disparities in Type 2 diabetes among adults will require multiple interventions society-wide in order to provide cumulative and synergistic effects that can result in sustained health practices and improved patient outcomes. One step in this approach is to encourage health care providers to deliver health promotion advice and counseling to their patients during routine office visits. Another is to link advice with readily available resources wherein an individual might be able to implement counsel. Therefore, the specific aim of this proposal is to evaluate the relative contribution of a multi-component, behavioral counseling intervention delivered by health care professionals versus the same behavioral counseling intervention when augmented by an interactive health promotion "telephone helpline" that will, among other things offer guidance on the availability of physical activity resources at Metro Parks facilities. In order to refine this intervention (Phase II) before it is executed, focus groups will first be conducted in Phase I with members of the target population in order to obtain feedback on the proposed intervention activities and materials. Qualitative findings and feasibility testing will be the basis for modifying the intervention.
Blood flow-induced endothelial shear stress has strong effect on endothelial function and development or progression of plaque formation. It is extensively accepted that low and/or oscillating shear stress causes endothelial dysfunction and is one of crucial factors in localizing early atherosclerosis .In contrary, normal and high shear stress is atheroma protective and is involved in compensatory remodeling . Most studies reported that the endothelial shear stress distribution in often idealized geometrical models of human coronary arteries was the subject of numerous investigations , and in these studies it was shown that the geometry of coronary arteries is the main determinant of the observed shear stress distribution. Generally, downstream of a plaque, low shear stress can be expected, Several cardiovascular active drugs have been shown to be cardio-protective for patients with obstructive coronary disease. Of these drugs, calcium channel blocker is one of most prescribed in everyday clinical practice. Ninomiya et al. reported calcium channel blocker was associated with increased coronary diameter and blood fluid with dose-dependent pattern in patients with normal or mild stenotic coronary artery. However, no reports on the dynamic change of endothelial shear stress after calcium channel blocker in -vitron were published so far. As a result, the aim of this study was to evaluate the effect of intra-venous injection of Nicardipine, one calcium channel blocker with shorter half-time, on the re-distribution of endothelial shear stress in patients with acute coronary syndrome and mild stenotic (\<50%) coronary artery disease.
PURPOSE:To form plural kinds of powdery cosmetics having sharp contours in a container, by raising and lowering a male mold piece optionally with a mold consisting of a mold frame without a partition plate, a container without a partition plate and the plural rising and lowering male mold pieces forming the male mold, and compressing and caking a powdery cosmetic. CONSTITUTION:A container 2 of suitable thickness is formed at the bottom of a cylindrical mold frame 1, and a male mold 5 is formed by plural male mold pieces (5A)- (5C) in contact with the bottom plate 3 of the container 2 and a peripheral rising plate 4, mutually in close contact with the sides, and sliding up and down. The right and left male mold pieces (5A) and (5C) are moved upward and different kinds of powdery cosmetics (8A) and (8C) in a given amount are fed and filled in gaps (7A) and (7C) and homogenized. The male mold pieces are then lowered to compress and cake the cosmetics, and solid powdery cosmetics (9A) and (9C) are formed. A solid cosmetic (9B) is then formed by the operation of the male mold piece (5B). The male mold 5 is then removed, and a fabric 11 having a shaped mark, etc. is pressed to the front side of the solid powdery cosmetic by an integral form adjusting piece 10 fitted in the mold frame 1, and the container 2 is then taken out of the mold frame 1.
Two 50-minute sessions per week. The manualized LOK walking protocol provides methods for progressing/tracking including a 5-minute overground walking session after the LOK to facilitate transfer of motor learning from the LOK to usual walking devices. The goal-based LOK program uses a standardized approach to progressing LOK body weight and guidance support and includes upper body activities while walking to encourage dual tasking and improved posture, and motor imagery practice.
TAS-102 is an oral agent, which consists of a combination of a novel antimetabolite 5-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI) that prevents degradation of FTD. It has demonstrated activity in chemorefractory metastatic colorectal cancer (mCRC) patients. In the Japanese randomized phase II trial, TAS-102 improved medial overall survival when compared to placebo (9.0 vs.6.6 months, Hazard Ratio (HR) 0.56) in patients with mCRC refractory to 5-fluorouracil (5-FU), irinotecan and oxaliplatin. Subsequently, a randomized phase III study conducted in 13 countries (RECOURSE trial) confirmed this benefit on overall survival when compared to placebo (7.1 months vs. 5.3 months, HR 0.68) in patients with refractory metastatic colorectal cancer (CRC) 5.

Oxaliplatin is a third generation platinum compound, which is active when used together with 5-FU in the treatment of mCRC (FOLFOX). FOLFOX chemotherapy, which is frequently combined with anti-angiogenic agent Bevacizumab, is widely accepted as the preferred first-line regimen in the treatment of this disease in the US. Oxaliplatin is also frequently reintroduced in more advanced settings. Reintroduction is seen after progression on maintenance therapy, after resolution of previous treatment limiting neuropathy, after disease recurrence post adjuvant treatment or post metastasectomy. In the control arm of a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer (OPTIMOX1 study), oxaliplatin was reintroduced in 27% of patients. Although patients derive clinical benefit when oxaliplatin is reintroduced, the response rates are not as robust as during initial exposures. Decreased efficacy may be at least in part due to prolonged exposure and resultant resistance to 5-FU, which is a backbone in maintenance and in oxaliplatin containing regimens. Hence, the investigators propose exploring the safety and efficacy of oxaliplatin in combination with an alternative anti-metabolite TAS-102 (TAS-OX).

TAS-102 has demonstrated activity in 5-FU refractory mCRC, so the investigators hypothesize that TAS-OX may serve as an alternative drug combination for patients who have progressed or recurred after FOLFOX, and who are candidates for additional oxaliplatin therapy.

This is a 2-part clinical trial with TAS-102 in combination with oxaliplatin. The first part will be a dose-finding run-in phase and will enroll 3-18 patients. The second part, the focus of this study, will be a single arm cohort , which will further evaluate the safety, as well as efficacy, of TAS-OX in the treatment of mCRC. The subjects in part 2 will be treated with the drug doses determined in Part 1 of the trial. Up to 50 patients will be enrolled in part 2. Anticipated enrollment may be as high as 68 patients. Maximum potential enrollment is listed under anticipated enrollment, below.
Background: Borderline personality disorder (BPD) affects about 2% of the American adult population. It is a very serious psychiatric disorder that places heavy demands on mental health resources. Behavior dysregulation (impulsivity, self-injurious acts, drinking or aggressive behavior) is considered one of the main features of BPD and is associated with significant clinical morbidity. Alcohol abuse is common among patients with BPD, and the co-morbid rates of alcoholism in BPD patients are estimated to be 30%. It has been hypothesized that alcohol misuse may be a manifestation of BPD's behavioral dysregulation. Also, BPD and alcohol dependence (AD) share a common underlying neurobiology. The co-occurrence of these disorders has been associated with increased rates of alcohol relapse, impulsive behaviors, greater resistance to treatment, and suicidal behavior. Effective treatment for patients with BPD and AD would result in markedly reduced health care costs and a substantial reduction in human distress and suffering. Despite dramatic advances in the treatment of BPD, to date, no single medication or types of medications have been uniquely identified as effective in treating BPD. Studies treating patients with co-morbid BPD and AD are expressly lacking.

Research Design and Methodology: This is an 8-week double-blind outpatient clinical trial of oral topiramate (250mg) vs placebo in individuals with BPD and AD. The study will be conducted at the West Haven, CT VA. Thirty men and women with a current diagnosis of BPD and AD will be enrolled. The State-Trait Anger Expression Inventory (STAEI) will be used to assess 5 aspects of aggression: state anger, trait anger, anger expressed inwardly, anger expressed outwardly, and anger control before and during treatment (weeks 0-8). The Timeline Follow-Back (TLFB) method will be used to document the degree of daily alcohol consumption before and during treatment (90 days before treatment, and weeks 0 - 8). Emergent side effects will be assessed using the modified version of the Systematic Assessment for Treatment Emergent Events (SAFTEE).
The invention belongs to the application technical field of medical feed additives, more particularly relates to preparation and application of an albendazole oxide hydrochloride premix for animals. In the premix, the albendazole oxide hydrochloride is taken as an active ingredient which is evenly mixed with a carrier zeolite powder to obtain the premix. The premix consists of the following parts of materials by weight: 1-20 parts of the albendazole oxide hydrochloride with less than 1% of water and 80-90 parts of the zeolite powder with less than 1% of water which are mixed to obtain a finished product by a conventional method. The premix prepared by the invention can be added to a compound feed for pigs, sheep and cattle for preventing parasitic diseases in animals. Administration dose is 5-10mg per kilogram of body weight based on the active ingredient. The premix prepared by the invention has the advantages of good performance, high bioavailability and quick residue elimination.
FIELD: veterinary virology. SUBSTANCE: organs infected with mink Aleutian disease (spleen, kidney, liver) were homogenized in the buffer system containing detergents and homogenate is treated by ultrasonic oscillation. For nonruptured cells precipitation homogenate is centrifuged twice. Polyethylene glycol is added to supernatant and mixture is kept for 4 hr at 4 C. Precipitated antigen is thickened by centrifugation, precipitate is dissolved in minimal buffer volume. Viral antigen is precipitated from the solution by ultracentrifugation at 30000g for 2 hr. Prepared viral preparation is purified from concomitant proteins by gel-chromatography on Sepharose 6B. EFFECT: high antigenic activity of viral antigen. 2 cl
INTRODUCTION: Nowadays, patients expect to be less spectacle dependent at all distances after cataract surgery. However, all intraocular lens (IOL) models that currently offer this function can also have negative visual effects. Aim of this study was therefore to compare the visual function performance of a novel and a conventional IOL solution for multifocality.
METHODS: Patients scheduled for bilateral cataract surgery were randomized to receive one of two different IOL combinations: either a binocular complementary extended depth-of-focus IOL set or a low near-add MIOL. Patients had visual acuity (VA) assessment at distance, intermediate, and near as well as evaluation of contrast sensitivity, halometry, and reading performance.
RESULTS: In total, 56 eyes of 28 patients were enrolled. At 6 months, there were no statistically significant differences in binocular VA between the ARTIS SYMBIOSE and the AT LARA. Contrast sensitivity, measured binocularly, at 1.5 cycles per degree under photopic conditions without glare was 1.54 logCS with the ARTIS SYMBIOSE and 1.43 logCS with the AT LARA (p = 0.046), under mesopic conditions with glare at 1.5 and 3 cycles per degree 1.31 logCS and 1.28 logCS with the ARTIS SYMBIOSE, respectively, compared to 0.58 logCS and 0.51 logCS with the AT LARA (p = 0.002; p = 0.006). Binocular halos and reading performance between both groups were similar.
CONCLUSION: There were no significant differences between both groups in VA at different distances, reading ability, or halometry. The contrast sensitivity at low spatial frequencies was better in the ARTIS SYMBIOSE group under photopic conditions without glare as well as mesopic conditions with glare, which could potentially improve quality of vision with these IOLs, especially under mesopic conditions.
Complications related to airway management rarely occur in the operating room; however, these complications can lead to life-threatening situations. There are many studies on the types and incidence rates of airway management complications in the perioperative period. However, although the types and incidence rates of airway complications have been investigated in these studies, the effect of airway equipment used in airway management on complications has not been investigated. There are many equipment used in airway management. Laryngoscopes, face masks, oral airway devices and many assistant airway management devices are used as basic equipment. Different airway equipment may be used in each center in each case. There is no standard between centers in this regard.

In this study, investigators will primarily research the types and incidence rates of airway complications seen in the perioperative period during airway management similar to the existing literature. In addition, unlike the literature, the relationship between the airway equipment used and perioperative airway complications will be investigated.
BACKGROUND AND AIM: The aim of this study was to investigate the comprehensive genetic effects of exploratory variants of LYPLAL1, GCKR, HSD17B13, TRIB1, APOC3, MBOAT7, and PARVB on pediatric nonalcoholic fatty liver disease in addition to the previously reported variants of TM6SF2, PNPLA3, and SAMM50 in Korean children.
METHODS: A prospective case-control study was conducted involving 309 patients diagnosed using ultrasound and 339 controls. Anthropometric measurements, liver function tests, and metabolic marker analysis were conducted, and fibrosis scores were calculated. Transient elastography was performed in 69 some patients with nonalcoholic fatty liver disease. TaqMan allelic discrimination assays were used for genotyping. The genetic risk scores were calculated using significant variants, namely, HSD17B13, PARVB, PNPLA3, SAMM50, and TM6SF2, to evaluate the additive effect.
RESULTS: Risk allele carriers of the PARVB variant showed significantly higher levels of aminotransferases, gamma-glutamyl transferase, alkaline phosphatase, pediatric nonalcoholic fatty liver disease fibrosis score, and aspartate aminotransferase/platelet ratio index. Individuals with a homozygous variant of HSD17B13 showed significantly lower levels of aminotransferase, gamma-glutamyl transferase, liver stiffness measurement, and aspartate aminotransferase/platelet ratio index than those with other genotypes. These parameters did not significantly differ among other variants of LYPLAL1, GCKR, TRIB1, APOC3, and MBOAT7. The genetic risk scores was identified as an independent risk factor for nonalcoholic fatty liver disease and had a positive association with severity.
CONCLUSION: HSD17B13 has protective effects on the severity of pediatric nonalcoholic fatty liver disease. Variants of HSD17B13, PARVB, PNPLA3, SAMM50, and TM6SF2 had an additive effect on nonalcoholic fatty liver disease.
This group will receive 5Hz Dorsomedial Prefrontal Cortex Transcranial Magnetic Stimulation, once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
PROBLEM TO BE SOLVED: To obtain a bathing agent which contains a substance selected from a naturally occurring specific compound, its derivatives and their salts, has both of skin moisture retention and body temperature retention after bathing and is particularly suitable for treatment and prevention of skin diseases, for example, atopic dermatitis. SOLUTION: This bathing agent contains one or two or more selected from saccharides, their derivatives or their physiologically permissible salts. The saccharides are preferably glucose, fructose, sucrose, mannitol, sorbitol, maltitol, xylitol, glucuronic acid, trehalose, alginic acid, hyaluronic acid, ribose, arabinose and deoxyribose. Particularly, ribose, arabinose and trehalose are preferred. The derivative of a saccharide is preferably its sulfuric ester and the salt is preferably a sulfate ester salt. The content of the active ingredient is preferably 1-100wt.%, particularly about 30-100wt.%.
The activation of inflammatory pathways plays an important contributory role in coronary plaque instability and subsequent rupture, which can lead to the development of acute coronary syndromes. Elevated levels of serum inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) represent independent risk factors for further cardiovascular events. Raised resting heart rate (HR) has been shown to be associated with cardiovascular events. Ivabradine is a new HR-reducing agent, which has demonstrated antianginal and anti-ischemic properties in patients with stable angina. In an atherosclerosis model, selective HR reduction with ivabradine has been shown to decrease markers of vascular oxidative stress, to improve endothelial function, and to reduce atherosclerotic plaque formation. We hypothesized that the addition of ivabradine to standard medical therapy has a beneficial effect on markers of inflammatory stress in acute coronary syndrome patients.
No treatment of deep bite. These participants will be evaluated during a 6-month follow-up period. In cases were significant problems arise during the follow-up period, the participant will be removed from the study and the appropriate treatment conducted.
### Teratogenic Effects:

####  Pregnancy Category C -

Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Teratology studies in the mouse demonstrated fluticasone propionate to be teratogenic (cleft palate) when administered subcutaneously in doses of 45 mcg/kg/day and 150 mcg/kg/day. This dose is approximately 14 and 45 times, respectively, the human topical dose of fluticasone propionate cream, 0.05%. There are no adequate and well-controlled studies in pregnant women. Fluticasone Propionate Cream, 0.05%, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.